Jump to section
To improve patient care by developing early detection technologies for diseases like sepsis.
As a fast-acting and life-threatening infection reaction, time is of the essence when diagnosing sepsis. Founded from academic research dating back to 2007, Cytovale has developed a rapid lab testing programme to quickly diagnose sepsis and other immune-mediated diseases in patients to minimize potentially life-altering and deadly effects.
After 6 years of clinical studies, IntelliSep hit the market in 2022 and generates a patient score that measures the probability of developing or having developed sepsis. Using this score, medical teams can quickly ascertain the next steps for treatment with more confidence, thanks to IntelliSep’s machine learning analytics capabilities.
Impressive Series D funding will go some way to growing the reach of Cytovale’s rapid lab tests. At present IntelliSep is only available at a pilot pool of hospitals and is the only test of its kind, so the market is wide open for expansion.
Steph
Company Specialist at Welcome to the Jungle
Oct 2024
$100m
SERIES D
Nov 2023
$84m
SERIES C
This company has top investors
Henry Tse
(Co-Founder & CTO)Previously a Researcher of Microfluidics at UCLA Henry Samueli School of Engineering and Applied Science.
Ajay Shah
(Co-Founder & CEO)Currently a Member of the Engineering Visitors Committee at Harvey Mudd College and a Researcher for the Cancer Centre at Massachusetts General Hospital.
Marketing